A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer

BACKGROUND: In this phase Ib/II open-label study, tumor immune suppression was targeted in patients with advanced refractory solid tumors and patients with recurrent/refractory non-small cell lung cancer (NSCLC) using galunisertib with nivolumab. METHODS: Eligible patients were ≥ 18 years old, had a...

Descripción completa

Detalles Bibliográficos
Autores principales: Nadal, Ernest, Saleh, Mansoor, Aix, Santiago Ponce, Ochoa-de-Olza, Maria, Patel, Sandip Pravin, Antonia, Scott, Zhao, Yumin, Gueorguieva, Ivelina, Man, Michael, Estrem, Shawn T., Liu, Jiangang, Avsar, Emin, Lin, Wen Hong, Benhadji, Karim A., Gandhi, Leena, Guba, Susan C., Diaz, Inmaculada Ales
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386782/
https://www.ncbi.nlm.nih.gov/pubmed/37507657
http://dx.doi.org/10.1186/s12885-023-11153-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386782/
https://www.ncbi.nlm.nih.gov/pubmed/37507657
http://dx.doi.org/10.1186/s12885-023-11153-1

Ejemplares similares